The report on the Global Epilepsy Drug Market gives an estimation of the development of the market based on historical studies and also provides forecasts on the basis of comprehensive research. The report gives a complete market analysis for the forecasted period from 2020 to 2026. The market is portioned into various segments with an in-depth outlook of the competitive outlook and a listing of the profiled key players. The market size in terms of revenue (USD MN) is calculated and provided for the study period along with the dynamics of the market such as the drivers and the restraints.
Study period considered for research of global epilepsy drug market:
- Base Year: 2019
- Estimated Year: 2020
- Forecast Till: 2026
A glimpse of the major drivers and restraints affecting the epilepsy drug market is mentioned below:
Drivers
- Rising incidence of neurological disorders
- Increasing road accident
- Higher incidence of birth related injuries
Restraints
- High cost of patented drugs
- Low accessibility to antiepileptic drugs in low and middle income countries
The report offers a value chain analysis that gives a comprehensive outlook of the epilepsy drug market. The attractiveness analysis of this market has also been included so as to evaluate the segments that are anticipated to be profitable during the forecast period.
The epilepsy drug market has been segmented based on drug types such as marketed drugs and pipeline drugs. The study incorporates periodic market estimates and forecasts. Each drug type has been analyzed based on the market size at regional and country levels. Further, marketed drugs has been segmented into first generation drug, second generation drug and third generation drug. First generation drugs has been further segmented into phenytoin, carbamazepine, oxycarbazepine, valproate, ethosuximide, primidone and phenobarbital. Second generation drugs has been segmented into levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide and zonisamide. Third generation drugs has been further segmented into lacosamide, perampanel, eslicarbazepine acetate and ezogabine/retigabine.
Geographically, the epilepsy drug market has been segmented into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The study details country-level aspects based on each segment and gives estimates in terms of market size.
The report also covers the complete competitive landscape of the global Epilepsy Drug market with company profiles of key players such as:
- Abbott Laboratories
- Eisai Co. Ltd
- GlaxoSmithKline plc
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- Sunovion Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
A detailed description of each has been included, with information in terms of headquarters, inception, stock listing, upcoming capacities, key mergers & acquisitions, financial overview, and recent developments. This analysis gives a thorough idea about the competitive positioning of market players. The report also gives information of epilepsy drug market’s mergers/acquisitions, partnerships, collaborations, new product launches, new product developments and other industry developments.
SEGMENTATIONS IN REPORT:
Epilepsy drug Market Analysis by Drug Type:
- Marketed Drugs
- First Generation Drugs
- Phenytoin
- Carbamazepine
- Oxycarbazepine
- Valproate
- Ethosuximide
- Primidone
- Phenobarbital
- Second Generation Drugs
- Levetiracetam
- Lamotrigine
- Topiramate
- Pregabalin
- Rufinamide
- Zonisamide
- Third Generation Drugs
- Lacosamide
- Perampanel
- Eslicarbazepine Acetate
- Ezogabine/Retigabine
- Pipeline Drugs
Epilepsy drug Market Analysis by Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East And Africa
The Global Epilepsy Drug Market has been exhibited in detail in the following chapters -
Chapter 1 Epilepsy Drug Market Preface
Chapter 2 Executive Summary
Chapter 3 Epilepsy Drug Industry Analysis
Chapter 4 Epilepsy Drug Market Value Chain Analysis
Chapter 5 Epilepsy Drug Market Analysis By Drug Type
Chapter 6 Epilepsy Drug Market Analysis By Geography
Chapter 7 Competitive Landscape Of Epilepsy Drug Companies
Chapter 8 Company Profiles Of Epilepsy Drug Industry
METHODOLOGY:
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.